Stockholder Alert: Robbins LLP Informs Investors of the Inspire Medical Systems, Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. due to allegations of misleading investors regarding the launch of its Inspire V device, which has faced significant challenges and poor demand [1][2][3] Company Overview - Inspire Medical Systems, Inc. is a medical technology company that develops and manufactures an implantable device for treating obstructive sleep apnea, known as "Inspire" [1] Allegations and Issues - The complaint alleges that the launch of the Inspire V device was poorly executed, with providers holding excess inventory and being hesitant to adopt the new treatment [2] - Key failures cited include inadequate training for treatment centers, lack of essential IT systems, and unpreparedness for Medicare reimbursement at launch [2] Financial Impact - On August 4, 2025, Inspire announced a significant reduction in its 2025 earnings guidance by over 80%, dropping from a range of $2.20 to $2.30 per share to $0.40 to $0.50 per share [3] - Following this announcement, the company's stock price plummeted by $42.04 per share, a decline of more than 32%, resulting in a loss of $1.2 billion in market capitalization in a single day [3] - From a high of $216.71 per share on September 23, 2024, the stock has decreased by nearly 60%, erasing billions in market value [3] Legal Proceedings - Shareholders interested in participating in the class action must submit their papers by January 5, 2026, to serve as lead plaintiff [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5]